Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis

Bibliographic Details
Main Authors:	Taylor, P, Downie, B, Zhuo, L, Hawtin, R, Liu, J, Mirza, A
Format:	Conference item
Published:	BMJ Publishing Group 2019

Similar Items

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotinib in MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3)
by: Taylor, PC, et al.
Published: (2020)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-severely Active Rheumatoid Arthritis (FINCH3)
by: Taylor, P, et al.
Published: (2020)

Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
by: Taylor, P, et al.
Published: (2020)

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotnib in adults with moderately-to-severely active rheumatoid arthritis with prior inadequate response to methotrexate (FINCH1)
by: Taylor, PC, et al.
Published: (2020)

The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2018)

Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2024)

Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid
by: Taylor, P, et al.
Published: (2018)

Filgotinib for the treatment of rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Filgotinib-treated rheumatoid arthritis patients with high baseline neutrophil-to-lymphocyte ratio show better clinical response rates and patient-reported outcomes
by: Taylor, P, et al.
Published: (2021)

Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials
by: Tarrant, J, et al.
Published: (2020)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
by: Przemysław J. Kotyla, et al.
Published: (2020-10-01)

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
by: Jeffrey R. Curtis, et al.
Published: (2023-12-01)

Takinib Inhibits Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts by Targeting the Janus Kinase-Signal Transducer and Activator of Transcription 3 (JAK/STAT3) Pathway
by: Paul M. Panipinto, et al.
Published: (2021-11-01)

Concomitant use of statins in filgotinib-treated patients with rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2021)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients
by: Taylor, P, et al.
Published: (2017)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
by: Alejandro Balsa, et al.
Published: (2023-09-01)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
by: Yoshiya Tanaka, et al.
Published: (2022-11-01)

Pain in rheumatoid arthritis - Could JAK inhibition be the answer?
by: Mehta, P, et al.
Published: (2020)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

JAK inhibitors in rheumatoid arthritis
by: Taylor, PC
Published: (2019)

Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate
by: Tanaka, Y, et al.
Published: (2023)

RUSSIAN AND INTERNATIONAL EXPERIENCE IN THE APPLICATION OF THE JANUS-KINASES INHIBITOR IN RHEUMATOID ARTHRITIS
by: D. E. Karateev, et al.
Published: (2017-05-01)

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-07-01)

A review of Janus kinase/signal transducer and activator of transcription signaling and cytokines in the pain mechanism of rheumatoid arthritis
by: Yue Xiong, et al.
Published: (2023-08-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
by: Mease, P, et al.
Published: (2018)

Effect of filgotinib on pain in patients with rheumatoid arthritis: results from phase 3 clinical trials
by: Pope, J, et al.
Published: (2021)

Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-11-01)

Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
by: A. E. Cheberda, et al.
Published: (2024-02-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

Upregulation of Peptide Transporters PEPT1 and PEPT2 by Janus Kinase JAK2
by: Zohreh Hosseinzadeh, et al.
Published: (2013-05-01)

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
by: Christian S. Thudium, et al.
Published: (2020-10-01)

Regulation of Voltage Gated K+ Channel KCNE1/KCNQ1 by the Janus Kinase JAK3
by: Jamshed Warsi, et al.
Published: (2015-12-01)

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr.
Published: (2022-09-01)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
by: Robert Harrington, et al.
Published: (2023-10-01)

Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
by: Jumpei Temmoku, et al.
Published: (2023-07-01)

JAK Inhibitors in Rheumatoid Arthritis
by: Kathryn Biddle, et al.
Published: (2022-08-01)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
by: Taylor, P
Published: (2019)

COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
by: Mansoor Khaledi, et al.
Published: (2022-08-01)